Similar articles

• Economic analysis of long-term reversible contraceptives. Focus on Implanon.

  Phillips CJ. Phillips CJ. Pharmacoeconomics. 2000 Feb;17(2):209-21. doi: 10.2165/00019053-200017020-00009. Pharmacoeconomics. 2000. PMID: 10947343 Clinical Trial.
• Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain.

  Lete I, Cristóbal I, Febrer L, Crespo C, Arbat A, Hernández FJ, Brosa M. Lete I, et al. Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):71-80. doi: 10.1016/j.ejogrb.2010.08.019. Epub 2010 Oct 15. Eur J Obstet Gynecol Reprod Biol. 2011. PMID: 20951492
• Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.

  Varney SJ, Guest JF. Varney SJ, et al. Pharmacoeconomics. 2004;22(17):1141-51. doi: 10.2165/00019053-200422170-00004. Pharmacoeconomics. 2004. PMID: 15612832
• Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices.

  Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012 Oct;120(4):983-8. doi: 10.1097/AOG.0b013e3182723b7d. Obstet Gynecol. 2012. PMID: 22996129
• Increasing LARC utilization: any woman, any place, any time.

  Hathaway M, Torres L, Vollett-Krech J, Wohltjen H. Hathaway M, et al. Clin Obstet Gynecol. 2014 Dec;57(4):718-30. doi: 10.1097/GRF.0000000000000071. Clin Obstet Gynecol. 2014. PMID: 25314089 Review.